Brendan Smith and Alec Stranahan's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2025
Question
Brendan from Cowen and Alec from BofA Securities asked how multiomic profiling for the RBM39 program will influence future patient enrollment and about the key differentiators of RBM39 versus other CDK-targeting assets.
Answer
Chief R&D and Commercial Officer Najat Khan explained that the multiomic approach revealed the target's importance across various replication stress pathways, which informed patient selection for the monotherapy dose escalation. She noted that further honing of the patient population will be based on incoming data. Khan differentiated RBM39 by stating it is not a kinase, unlike CDK12, and thus avoids the homology challenges with CDK13, offering better selectivity.